Our finding in conjunction with the known mechanism of CHL1 may suggest the increase in the CHL1 gene expression after pirenperone treatment possibly rescues FXS symptoms by modulating synaptic development or increasing the synaptic coverage of neurons. Here, CHL1 is linked to fragile X syndrome.